Form 4 for ALKS Alkermes plc.
Accepted 2024-02-21 00:00:00 ET · period of report 2024-02-18 · accession 0001127602-24-006173 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2024-02-21 | 2024-02-18+ | ALKS | LANDINE MICHAEL J | SVP, Corp Dev, Alkermes, Inc | M - OptEx | — | +9,909 | 273.2K | +4% | — |
| DM | 2024-02-21 | 2024-02-18+ | ALKS | LANDINE MICHAEL J | SVP, Corp Dev, Alkermes, Inc | F - Tax | $31.19 | -2,914 | 271.9K | -1% | -$90.9K |
| DM | 2024-02-21 | 2023-11-17 | ALKS | LANDINE MICHAEL J | SVP, Corp Dev, Alkermes, Inc | J - Other | $35.24 | +14.5K | 44.9K | +48% | +$510.1K |
| DM | 2024-02-21 | 2024-02-18+ | ALKS | LANDINE MICHAEL J | SVP, Corp Dev, Alkermes, Inc | M - OptEx | — | -9,909 | 8,897 | -53% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2024-02-20 | M | A | 5,461 | — | 277,345 | D | — | — | (F1) Each restricted stock unit represents a contingent right to receive one ordinary share. |
| 2 | Common | Ordinary Shares | 2024-02-20 | F | D | 1,606 | $30.39 | 275,739 | D | — | — | |
| 3 | Common | Ordinary Shares | 2024-02-18 | M | A | 4,448 | — | 273,192 | D | — | — | (F1) Each restricted stock unit represents a contingent right to receive one ordinary share. |
| 4 | Common | Ordinary Shares | 2024-02-18 | F | D | 1,308 | $32.18 | 271,884 | D | — | — | |
| 5 | Derivative | Employee Stock Option (Right to Buy) | 2023-11-17 | J | A | 999 | $46.24 | 50,999 | D | $46.24 · — to 2024-03-03 | 999 Ordinary Shares | (F2) Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. (F3) These options are fully vested in accordance with their terms. |
| 6 | Derivative | Restricted Stock Unit Award | 2024-02-20 | M | D | 5,461 | — | 0 | D | — · — to — | 5,461 Ordinary Shares | (F1) Each restricted stock unit represents a contingent right to receive one ordinary share. (F5) Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/20/2021. |
| 7 | Derivative | Employee Stock Option (Right to Buy) | 2023-11-17 | J | A | 1,519 | $31.64 | 77,519 | D | $31.64 · — to 2026-02-28 | 1,519 Ordinary Shares | (F2) Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. (F3) These options are fully vested in accordance with their terms. |
| 8 | Derivative | Employee Stock Option (Right to Buy) | 2023-11-17 | J | A | 999 | $53.50 | 50,999 | D | $53.50 · — to 2027-02-17 | 999 Ordinary Shares | (F2) Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. (F3) These options are fully vested in accordance with their terms. |
| 9 | Derivative | Employee Stock Option (Right to Buy) | 2023-11-17 | J | A | 1,089 | $65.94 | 55,589 | D | $65.94 · — to 2028-02-16 | 1,089 Ordinary Shares | (F2) Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. (F3) These options are fully vested in accordance with their terms. |
| 10 | Derivative | Employee Stock Option (Right to Buy) | 2023-11-17 | J | A | 1,811 | $31.93 | 92,411 | D | $31.93 · — to 2029-02-21 | 1,811 Ordinary Shares | (F2) Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. (F3) These options are fully vested in accordance with their terms. |
| 11 | Derivative | Employee Stock Option (Right to Buy) | 2023-11-17 | J | A | 1,790 | $20.03 | 91,335 | D | $20.03 · — to 2030-02-20 | 1,790 Ordinary Shares | (F2) Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. (F4) Shares subject to the stock option award vest and become exercisable in four equal annual installments commencing on 2/20/2021. |
| 12 | Derivative | Restricted Stock Unit Award | 2023-11-17 | J | A | 107 | — | 5,461 | D | — · — to — | 107 Ordinary Shares | (F2) Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. (F1) Each restricted stock unit represents a contingent right to receive one ordinary share. (F5) Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/20/2021. |
| 13 | Derivative | Employee Stock Option (Right to Buy) | 2023-11-17 | J | A | 1,809 | $19.34 | 92,296 | D | $19.34 · — to 2031-02-22 | 1,809 Ordinary Shares | (F2) Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. (F6) Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/22/2022. |
| 14 | Derivative | Restricted Stock Unit Award | 2023-11-17 | J | A | 221 | — | 11,309 | D | — · — to — | 221 Ordinary Shares | (F2) Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. (F1) Each restricted stock unit represents a contingent right to receive one ordinary share. (F7) Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/22/2022. |
| 15 | Derivative | Employee Stock Option (Right to Buy) | 2023-11-17 | J | A | 1,394 | $24.59 | 71,171 | D | $24.59 · — to 2032-02-18 | 1,394 Ordinary Shares | (F2) Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. (F8) Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/18/2023. |
| 16 | Derivative | Restricted Stock Unit Award | 2023-11-17 | J | A | 261 | — | 13,345 | D | — · — to — | 261 Ordinary Shares | (F2) Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. (F1) Each restricted stock unit represents a contingent right to receive one ordinary share. (F9) Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/18/2023. |
| 17 | Derivative | Employee Stock Option (Right to Buy) | 2023-11-17 | J | A | 1,279 | $26.82 | 65,241 | D | $26.82 · — to 2033-02-23 | 1,279 Ordinary Shares | (F2) Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. (F10) Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/23/2024. |
| 18 | Derivative | Restricted Stock Unit Award | 2023-11-17 | J | A | 319 | — | 16,310 | D | — · — to — | 319 Ordinary Shares | (F2) Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. (F1) Each restricted stock unit represents a contingent right to receive one ordinary share. (F11) Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/23/2024. |
| 19 | Derivative | Restricted Stock Unit Award | 2024-02-18 | M | D | 4,448 | — | 8,897 | D | — · — to — | 4,448 Ordinary Shares | (F1) Each restricted stock unit represents a contingent right to receive one ordinary share. (F9) Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/18/2023. |
| 20 | Derivative | Employee Stock Option (Right to Buy) | 2023-11-17 | J | A | 879 | $69.83 | 44,879 | D | $69.83 · — to 2025-02-26 | 879 Ordinary Shares | (F2) Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. (F3) These options are fully vested in accordance with their terms. |